Your session is about to expire
← Back to Search
Loncastuximab Tesirine for Marginal Zone Lymphoma
Study Summary
This trial is testing if a new cancer drug is effective and safe for people with certain types of immune cell cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had treatment including an anti-CD20 antibody for my condition but it didn't fully work.I am 18 years old or older.I am unable to make my own medical decisions.I am still recovering from major surgery complications.My lymphoma has changed into a more aggressive form.I have a conjunctival eye lesion that is at least 1 cm wide or I have multiple lesions.I do not have heart failure, uncontrolled heart rhythm problems, recent stroke, severe liver disease, or autoimmune disorders.I am not currently receiving any cancer treatments.I have not taken any cancer drugs or experimental medications recently.I meet one of the required criteria to start treatment.I have hepatitis B or C.My cancer is a type of marginal zone lymphoma.I have recently had a stem cell transplant.I am HIV positive.I have no ongoing side effects from previous cancer treatments.I have a long-term or currently active infection.I have had brain lymphoma or cancer spread to the lining of my brain and spinal cord.My cancer can be seen on scans.I have been treated with anti-CD19 therapy before.I haven't had any other cancer in the past 3 years, except for certain types.My skin lesion is at least 1.5 cm wide or I have multiple skin lesions.My stomach cancer's type and stage are confirmed by biopsy.I can take care of myself and am up and about more than half of my waking hours.I am willing to undergo a biopsy of my lymph node or tissue.My spleen cancer has spread to my bone marrow, confirmed by tests.My blood, liver, and kidney tests are all within normal ranges.
- Group 1: Loncastuximab tesirine Cycles 1-6
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are enrolled in this clinical investigation?
"Affirmative. According to clinicaltrials.gov, this medical investigation is still enrolling participants since it was first posted on June 21st 2022 and updated most recently on July 12th 2022. It seeks out 50 individuals from a single research site."
What is the ultimate purpose of this clinical research project?
"The trial's primary outcome of loncastuximab tesirine in those with relapsed/refractory cancer will be evaluated over the course of 12 months. This assessment will include an overall response rate (CR+PR) and partial response rates determined by Cheson or revised Lugano criteria (based on PET avidity). Secondary objectives are also established, such as measuring complete and partial responses per modified MZL at 6 and 12 months respectively."
Is admission to the trial still open for volunteers?
"According to clinicaltrials.gov, this medical trial is actively seeking qualified participants. It was initially announced on June 21st 2022 and recently modified on July 12th 2022."
Is Loncastuximab tesirine 150 µg/Kg a secure medication for patients?
"The safety of Loncastuximab tesirine 150 µg/Kg has been rated a 2 by our Power team, as there is some evidence to suggest it's safe but no data that can confirm its efficacy."
Share this study with friends
Copy Link
Messenger